Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACY-1215 and Nab-paclitaxel in Metastatic Breast Cancer
NCT02632071Phase 1Completed
- Sponsor
- Columbia University
- Start
- Mar 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ricolinostat in breast cancer (4 arms), sponsored by Columbia University. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2016; status: completed.
02
Drugs
ricolinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02632071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632071.